BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Groot VP, Blair AB, Gemenetzis G, Ding D, Burkhart RA, Yu J, Borel Rinkes IH, Molenaar IQ, Cameron JL, Weiss MJ, Wolfgang CL, He J. Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. European Journal of Surgical Oncology 2019;45:1674-83. [DOI: 10.1016/j.ejso.2019.04.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Halle-Smith JM, Hall L, Daamen LA, Hodson J, Pande R, Young A, Jamieson NB, Lamarca A, van Santvoort HC, Molenaar IQ, Valle JW, Roberts KJ. Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Eur J Surg Oncol 2021;47:2248-55. [PMID: 34034941 DOI: 10.1016/j.ejso.2021.04.031] [Reference Citation Analysis]
2 Blair AB, Yin LD, Pu N, Yu J, Groot VP, Rozich NS, Javed AA, Zheng L, Cameron JL, Burkhart RA, Weiss MJ, Wolfgang CL, He J. Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer. Ann Surg 2021;274:162-9. [PMID: 32304375 DOI: 10.1097/SLA.0000000000003570] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
3 Balzano G, Pecorelli N, Falconi M, Reni M. Comment on "Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer": What Is Good for the Surgeon Is Just as Good for the Patient? Ann Surg 2020;271:e106-7. [PMID: 31804386 DOI: 10.1097/SLA.0000000000003655] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Roalsø M, Aunan JR, Søreide K. Refined TNM-staging for pancreatic adenocarcinoma - Real progress or much ado about nothing? Eur J Surg Oncol 2020;46:1554-7. [PMID: 32107094 DOI: 10.1016/j.ejso.2020.02.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Bellomo G, Rainer C, Quaranta V, Astuti Y, Raymant M, Boyd E, Stafferton R, Campbell F, Ghaneh P, Halloran CM, Hammond DE, Morton JP, Palmer D, Vimalachandran D, Jones R, Mielgo A, Schmid MC. Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis. Gut 2022:gutjnl-2021-325272. [PMID: 35022267 DOI: 10.1136/gutjnl-2021-325272] [Reference Citation Analysis]
6 Chawla A. Contemporary trials evaluating neoadjuvant therapy for resectable pancreatic cancer. J Surg Oncol 2021;123:1423-31. [PMID: 33831254 DOI: 10.1002/jso.26393] [Reference Citation Analysis]
7 Kamarajah SK, White SA, Naffouje SA, Salti GI, Dahdaleh F. Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study. Ann Surg Oncol 2021. [PMID: 33786676 DOI: 10.1245/s10434-021-09823-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Limbu Y, Regmee S, Ghimire R, Maharjan DK, Thapa PB. Arterial Divestment and Resection in Post-neoadjuvant Pancreatic Adenocarcinoma. Cureus 2021;13:e20275. [PMID: 34912651 DOI: 10.7759/cureus.20275] [Reference Citation Analysis]
9 Zhang C, Wu R, Smith LM, Baine M, Lin C, Reames BN. An evaluation of adjuvant chemotherapy following neoadjuvant chemotherapy and resection for borderline resectable and locally advanced pancreatic cancer. The American Journal of Surgery 2021. [DOI: 10.1016/j.amjsurg.2021.12.018] [Reference Citation Analysis]
10 Rangelova E, Bratlie SO. How to select the most appropriate adjuvant treatment after neoadjuvant treatment and resection for locally advanced pancreatic cancer? J Gastrointest Oncol 2021;12:2521-35. [PMID: 34790413 DOI: 10.21037/jgo-21-474] [Reference Citation Analysis]
11 Heger U, Mack C, Tjaden C, Pan F, Pausch T, Hinz U, Sommer CM, Hackert T. Open irreversible electroporation for isolated local recurrence of pancreatic ductal adenocarcinoma after primary surgery. Pancreatology 2021;21:1349-55. [PMID: 34404600 DOI: 10.1016/j.pan.2021.08.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Daamen LA, Groot VP, Intven MPW, Besselink MG, Busch OR, Koerkamp BG, Mohammad NH, Hermans JJ, van Laarhoven HWM, Nuyttens JJ, Wilmink JW, van Santvoort HC, Molenaar IQ, Stommel MWJ; Dutch Pancreatic Cancer Group. Postoperative surveillance of pancreatic cancer patients. Eur J Surg Oncol 2019;45:1770-7. [PMID: 31204168 DOI: 10.1016/j.ejso.2019.05.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
13 Klotz R, Hackert T, Heger P, Probst P, Hinz U, Loos M, Berchtold C, Mehrabi A, Schneider M, Müller-Stich BP, Strobel O, Diener MK, Mihaljevic AL, Büchler MW. The TRIANGLE operation for pancreatic head and body cancers: early postoperative outcomes. HPB (Oxford) 2021:S1365-182X(21)00614-6. [PMID: 34294523 DOI: 10.1016/j.hpb.2021.06.432] [Reference Citation Analysis]
14 Wu YHA, Oba A, Lin R, Watanabe S, Meguid C, Schulick RD, Del Chiaro M. Selecting surgical candidates with locally advanced pancreatic cancer: a review for modern pancreatology. J Gastrointest Oncol 2021;12:2475-83. [PMID: 34790408 DOI: 10.21037/jgo-21-119] [Reference Citation Analysis]
15 Kubo H, Ohgi K, Sugiura T, Ashida R, Yamada M, Otsuka S, Yamazaki K, Todaka A, Sasaki K, Uesaka K. The Association Between Neoadjuvant Therapy and Pathological Outcomes in Pancreatic Cancer Patients After Resection: Prognostic Significance of Microscopic Venous Invasion. Ann Surg Oncol. [DOI: 10.1245/s10434-022-11628-8] [Reference Citation Analysis]
16 He C, Cai Z, Zhang Y, Lin X. Comparative Recurrence Analysis of Pancreatic Adenocarcinoma after Resection. J Oncol 2021;2021:3809095. [PMID: 34721578 DOI: 10.1155/2021/3809095] [Reference Citation Analysis]
17 Safi SA, Haeberle L, Fluegen G, Lehwald-Tywuschik N, Krieg A, Keitel V, Luedde T, Esposito I, Rehders A, Knoefel WT. Mesopancreatic excision for pancreatic ductal adenocarcinoma improves local disease control and survival. Pancreatology 2021;21:787-95. [PMID: 33775563 DOI: 10.1016/j.pan.2021.02.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Ratnayake B, Savastyuk AY, Nayar M, Wilson CH, Windsor JA, Roberts K, French JJ, Pandanaboyana S. Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis. J Clin Med 2020;9:E2132. [PMID: 32640720 DOI: 10.3390/jcm9072132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
19 Choi YJ, Byun Y, Kang JS, Kim HS, Han Y, Kim H, Kwon W, Oh DY, Paik WH, Lee SH, Ryu JK, Kim YT, Lee K, Chie EK, Jang JY. Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX. Gut Liver. 2020;. [PMID: 32839360 DOI: 10.5009/gnl20070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 He C, Huang X, Zhang Y, Cai Z, Lin X, Li S. A Quantitative Clinicopathological Signature for Predicting Recurrence Risk of Pancreatic Ductal Adenocarcinoma After Radical Resection. Front Oncol 2019;9:1197. [PMID: 31781499 DOI: 10.3389/fonc.2019.01197] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
21 Seppälä TT, Zimmerman JW, Sereni E, Plenker D, Suri R, Rozich N, Blair A, Thomas DL 2nd, Teinor J, Javed A, Patel H, Cameron JL, Burns WR, He J, Tuveson DA, Jaffee EM, Eshleman J, Szabolcs A, Ryan DP, Ting DT, Wolfgang CL, Burkhart RA. Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. Ann Surg 2020;272:427-35. [PMID: 32657929 DOI: 10.1097/SLA.0000000000004200] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
22 Fujii Y, Kamachi H, Matsuzawa F, Mizukami T, Kobayashi N, Fukai M, Taketomi A. Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreatic cancer cells and enhances gemcitabine sensitivity in a xenograft mouse model. Invest New Drugs 2021. [PMID: 33905019 DOI: 10.1007/s10637-021-01118-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Choi SH, Kim HY, Hwang HK, Kang CM, Lee WJ. Oncologic Impact of Local Recurrence in Resected Pancreatic Cancer and Topographic Preference in Local Recurrence Patterns According to Tumor Location. Pancreas 2020;49:1290-6. [PMID: 33122516 DOI: 10.1097/MPA.0000000000001679] [Reference Citation Analysis]
24 Diener MK, Mihaljevic AL, Strobel O, Loos M, Schmidt T, Schneider M, Berchtold C, Mehrabi A, Müller-Stich BP, Jiang K, Neoptolemos JP, Hackert T, Miao Y, Büchler MW. Periarterial divestment in pancreatic cancer surgery. Surgery 2021;169:1019-25. [PMID: 33032819 DOI: 10.1016/j.surg.2020.08.030] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]